People with chronic lymphocytic leukemia (CLL) may have a higher risk of developing skin cancers, such as melanoma, than those without CLL. They may also have less positive outlooks if they develop ...

There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

In a Danish study, patients with chronic lymphocytic leukemia (CLL) showed a higher risk for skin cancer, metastasis, and death than matched individuals at 10 years. Researchers conducted a population ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Academic cancer centers show significantly better survival outcomes for CLL and MCL patients compared with community settings. Younger patients, high-risk disease features, and higher clinical trial ...

One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients. By participating in clinical trials, patients with cancer have the opportunity to find ...

Consuming high levels of the sugar substitute sucralose was linked with a worse response to immunotherapy and poorer survival in patients with melanoma and lung cancer. (Cancer Discovery) The FDA ...